CN Mobile Logo

Search form


Dave Levitan

Dave Levitan

Posts by Author

In prostate cancer patients, a PSA nadir value of > 0.5 ng/mL after radiation therapy and androgen deprivation therapy can identify patients at a high risk of death.

The PD-1 inhibitor pembrolizumab showed promising antitumor activity and acceptable safety in patients with advanced urothelial cancer, in a phase I trial.

Women with endometrioid ovarian cancer present at a younger age and with earlier stage disease than those with serous ovarian cancer, according to a new analysis. The earlier presentation resulted in better 5- and 10-year overall survival rates as well.

Certain patient-reported outcomes including fatigue and emotional support are associated with survival outcomes in patients with early-stage colorectal cancer.

Adding bortezomib to lenalidomide and dexamethasone improved progression-free and overall survival in patients with newly diagnosed multiple myeloma who were not planned for immediate stem-cell transplant.

Advanced colorectal cancer patients with BRAF mutations have markedly worse prognosis than non-mutant patients, according to a large analysis. Post-progression survival in particular is worse among BRAF-mutant patients.

In patients with upper tract urothelial carcinoma, adjuvant chemotherapy following radical nephroureterectomy confers a survival advantage compared with observation following radical nephroureterectomy.

Adding cetuximab to chemoradiation yielded better locoregional failure rates than historical data in a small trial of patients with squamous cell carcinoma of the anal canal, but the treatment resulted in substantial toxicity.

Brain metastases from primary breast cancer tumors often acquire clinically actionable genetic alterations, according to a small study. About one fifth of ERBB2/HER2-negative cases switched to HER2-positivity in the brain metastases.

A delay in initiation of adjuvant chemotherapy following resection for non–small-cell lung cancer was not associated with any increase in mortality.


By clicking Accept, you agree to become a member of the UBM Medica Community.